# frontMIND (NCT04824092)

> Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04824092
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Incyte Corporation
- Conditions: Diffuse Large B-cell Lymphoma
- Interventions: Tafasitamab; Lenalidomide; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone; Tafasitamab placebo; Lenalidomide placebo
- Enrollment: 899
- Primary outcome: PFS-INV

## Commentary we found

- X threads: 40
- YouTube: 31
- Podcasts: 23
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=frontmind-nct04824092

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04824092", "email": "<work email>"}; the inbox owner confirms by the emailed link.